Therapeutic drug monitoring in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab: insights from a prospective real-world study

Patients on IV IFX can be safely switched to SC treatment when initial dosing is guided by the prior IV regimen and subsequently individualized based on serum drug concentrations. Fixed SC dosing based solely on previous IV dosing may be appropriate for patients on standard IV doses but less reliable in those treated with higher doses.